Disc Medicine (IRON) Change in Accured Expenses (2020 - 2026)
Disc Medicine (IRON) reported Change in Accured Expenses of -$8.7 million for Q1 2026, down 136.76% year-over-year from $23.8 million in Q1 2025, and down 296.45% on a QoQ basis from $4.4 million in Q4 2025.
Disc Medicine (IRON) has 7 years of Change in Accured Expenses data on file, last reported at -$8.7 million in Q1 2026.
- Quarterly Change in Accured Expenses fell 136.76% year-over-year to -$8.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.8 million (up 69.46% YoY) and the FY2025 annual result came in at $6.9 million, up 309.4% from the prior year.
- Change in Accured Expenses eased to -$8.7 million in Q1 2026 per IRON's latest filing, from $4.4 million in the prior quarter.
- Across five years, Change in Accured Expenses topped out at $5.0 million in Q3 2025 and bottomed at -$8.7 million in Q1 2026.
- The 5-year median for Change in Accured Expenses is $942000.0 (2023), against an average of $186470.6.
- The widest annual swing landed in 2022, when Change in Accured Expenses jumped 3824.53%; it then slumped 11477.78% in 2023.
- Tracing IRON's Change in Accured Expenses over 5 years: stood at $2.0 million in 2022, then jumped by 36.17% to $2.7 million in 2023, then decreased by 13.39% to $2.3 million in 2024, then jumped by 90.98% to $4.4 million in 2025, then slumped by 296.45% to -$8.7 million in 2026.
- Per Business Quant, the three latest IRON Change in Accured Expenses figures stand at -$8.7 million (Q1 2026), $4.4 million (Q4 2025), and $5.0 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 931,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 70.50 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 107.70 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -176.03 Mn |
| 10 | Disc Medicine | 2.76 Bn | 2.03 Bn | - | -8.73 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -8.73 Mn |
| Mar 31, 2026 | -8.73 Mn |
| Dec 31, 2025 | 4.45 Mn |
| Dec 31, 2025 | 4.45 Mn |
| Sep 30, 2025 | 4.95 Mn |
| Sep 30, 2025 | 4.95 Mn |
| Jun 30, 2025 | 1.17 Mn |
| Jun 30, 2025 | 1.17 Mn |
| Mar 31, 2025 | -3.69 Mn |
| Mar 31, 2025 | -3.69 Mn |
| Dec 31, 2024 | 2.33 Mn |
| Dec 31, 2024 | 2.33 Mn |
| Sep 30, 2024 | 1.48 Mn |
| Sep 30, 2024 | 1.48 Mn |
| Jun 30, 2024 | 962,000.00 |
| Jun 30, 2024 | 962,000.00 |
| Mar 31, 2024 | -3.09 Mn |
| Mar 31, 2024 | -3.09 Mn |
| Dec 31, 2023 | 2.69 Mn |
| Dec 31, 2023 | 2.69 Mn |
| Sep 30, 2023 | 942,000.00 |
| Sep 30, 2023 | 942,000.00 |
| Jun 30, 2023 | 293,000.00 |
| Jun 30, 2023 | 293,000.00 |
| Mar 31, 2023 | -2.08 Mn |
| Mar 31, 2023 | -2.08 Mn |
| Dec 31, 2022 | 1.97 Mn |
| Dec 31, 2022 | 1.97 Mn |
| Sep 30, 2022 | 448,000.00 |
| Sep 30, 2022 | 448,000.00 |
| Jun 30, 2022 | -902,000.00 |
| Jun 30, 2022 | -902,000.00 |
| Mar 31, 2022 | -18,000.00 |
| Mar 31, 2022 | -18,000.00 |
| Dec 31, 2021 | -53,000.00 |
| Dec 31, 2021 | -53,000.00 |
| Sep 30, 2021 | 1.71 Mn |
| Sep 30, 2021 | 1.71 Mn |
| Jun 30, 2021 | 238,000.00 |
| Jun 30, 2021 | 238,000.00 |
| Mar 31, 2021 | -348,000.00 |
| Mar 31, 2021 | -348,000.00 |
| Dec 31, 2020 | 422,588.00 |
| Dec 31, 2020 | 422,588.00 |
| Sep 30, 2020 | 391,999.00 |
| Sep 30, 2020 | 391,999.00 |
| Jun 30, 2020 | 674,000.00 |
| Jun 30, 2020 | 674,000.00 |
| Mar 31, 2020 | -1.23 Mn |
| Mar 31, 2020 | -1.23 Mn |